Kidney Cancer - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 284 Pages - SKU: GMD6775826
|
|
Kidney Cancer - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H1 2012', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Kidney Cancer.
- A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Kidney Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Kidney Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Kidney Cancer
- Kidney Cancer Therapeutics under Development by Companies
- Kidney Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Kidney Cancer Therapeutics - Products under Development by Companies
- Kidney Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Kidney Cancer Therapeutics Development
- Bristol-Myers Squibb Company
- Genzyme Corporation
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Amgen Inc.
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Seattle Genetics, Inc.
- Genentech, Inc.
- Merck & Co., Inc.
- Emergent BioSolutions Inc.
- Oxford BioMedica plc
- Light Sciences Oncology, Inc.
- Novartis AG
- ImClone Systems Incorporated
- Astellas Pharma Inc.
- Eisai Co., Ltd.
- Ono Pharmaceutical Co., Ltd.
- OSI Pharmaceuticals, Inc.
- Pfizer Inc.
- Taiho Pharmaceutical Co., Ltd.
- Exelixis, Inc.
- Alfacell Corporation
- Celgene Corporation
- Bayer AG
- MannKind Corporation
- 3SBio Inc.
- EntreMed, Inc.
- Celldex Therapeutics, Inc.
- Active Biotech AB
- AEterna Zentaris Inc.
- AIDA Pharmaceuticals, Inc.
- Lorus Therapeutics Inc
- Bionomics Limited
- Northwest Biotherapeutics, Inc.
- Cleveland BioLabs, Inc.
- Patrys Limited
- Keryx Biopharmaceuticals, Inc.
- ARQULE, INC
- Allos Therapeutics, Inc
- Flamel Technologies S.A.
- Dendreon Corporation
- Green Cross Corporation
- MOLOGEN AG
- OncoTherapy Science, Inc.
- Threshold Pharmaceuticals, Inc.
- Innate Pharma SA
- Protox Therapeutics Inc.
- Rexahn Pharmaceuticals, Inc.
- Debiopharm Group
- Antisense Pharma GmbH
- Wilex AG
- Philogen S.p.A.
- Cadila Pharmaceuticals Ltd.
- ERYtech Pharma
- immatics biotechnologies GmbH
- Curacyte AG
- Argos Therapeutics, Inc.
- Cytheris SA
- Altor BioScience Corporation
- AgrenVec, S.L.
- Alethia Biotherapeutics Inc.
- Gene Signal International SA.
- MacroGenics, Inc.
- Pivotal BioSciences, Inc.
- Neotropix, Inc.
- Jennerex Biotherapeutics, Inc.
- Endocyte, Inc.
- Advenchen Laboratories, LLC
- Immutep S.A.
- Syndax Pharmaceuticals, Inc.
- Esperance Pharmaceuticals, Inc.
- Welichem Biotech Inc.
- Tigris Pharmaceuticals, Inc.
- AVEO Pharmaceuticals, Inc.
- KAHR medical Ltd.
- Advanced Cancer Therapeutics
- Medical Enzymes AG
- IkerChem S.L.
- Immunovative Therapies, Ltd.
- Kidney Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Nexavar - Drug Profile
- Axitinib - Drug Profile
- Axitinib - Drug Profile
- Sutent - Drug Profile
- ANYARA - Drug Profile
- IMA901 - Drug Profile
- TroVax - Drug Profile
- NuLeusin - Drug Profile
- Tivozanib - Drug Profile
- Rencarex - Drug Profile
- Dovitinib - Drug Profile
- Aldesleukin for Kidney Cancer - Drug Profile
- Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile
- Bevacizumab + Torisel - Drug Profile
- Gemcitabine + Cisplatin + Bevacizumab - Drug Profile
- Interferon Alfa-2B + Bevacizumab - Drug Profile
- Interferon Alfa-2B - Drug Profile
- BAY43-9006 - Drug Profile
- Sunitinib - Drug Profile
- Dactinomycin + Doxorubicin + Vincristine - Drug Profile
- Sorafenib Tosylate - Drug Profile
- Recombinant Interferon Alfa + Isotretinoin - Drug Profile
- Interferon Alfa + CCI-779 - Drug Profile
- BCG Vaccine + Iressa - Drug Profile
- Interleukin-2 - Drug Profile
- Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile
- RAD001 - Drug Profile
- TroVax + IL-2 - Drug Profile
- Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile
- Filgrastim + Doxorubicin + Ifosfamide - Drug Profile
- Interferon-Alpha - Drug Profile
- Votrient - Drug Profile
- Everolimus + Bevacizumab - Drug Profile
- ANYARA + Interferon Alpha - Drug Profile
- Sunitinib - Drug Profile
- Interferon-alpha - Drug Profile
- Interleukin 2 + Interferon-alpha2 - Drug Profile
- Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile
- Sorafenib - Drug Profile
- Sorafenib + Sunitinib - Drug Profile
- bevacizumab + recombinant interferon alfa - Drug Profile
- Carboplatin + Methotrexate + Vinblastine - Drug Profile
- aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile
- Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile
- Doxorubicin hydrochloride - Drug Profile
- Gemcitabine + Cisplatin - Drug Profile
- Sunitinib - Drug Profile
- Recombinant Gamma Interferon - Drug Profile
- Cisplatin + Radiation Therapy - Drug Profile
- Sunitinib - Drug Profile
- Bevacizumab + Interferon Alfa-2a - Drug Profile
- Kidney Cancer Therapeutics - Drug Profile Updates
- Kidney Cancer Therapeutics - Discontinued Products
- Kidney Cancer Therapeutics - Dormant Products
- Kidney Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Kidney Cancer, H1 2012
- Products under Development for Kidney Cancer - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Development by Companies, H1 2012 (Contd..1)
- Number of Products under Development by Companies, H1 2012 (Contd..2)
- Number of Products under Development by Companies, H1 2012 (Contd..3)
- Number of Products under Development by Companies, H1 2012 (Contd..4)
- Number of Products under Development by Companies, H1 2012 (Contd..5)
- Number of Products under Development by Companies, H1 2012 (Contd..6)
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Development by Companies, H1 2012 (Contd..2)
- Products under Development by Companies, H1 2012 (Contd..3)
- Products under Development by Companies, H1 2012 (Contd..4)
- Products under Development by Companies, H1 2012 (Contd..5)
- Products under Development by Companies, H1 2012 (Contd..6)
- Products under Development by Companies, H1 2012 (Contd..7)
- Products under Development by Companies, H1 2012 (Contd..8)
- Products under Investigation by Universities/Institutes, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..25)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..26)
- Bristol-Myers Squibb Company, H1 2012
- Genzyme Corporation, H1 2012
- Boehringer Ingelheim GmbH, H1 2012
- F. Hoffmann-La Roche Ltd., H1 2012
- Kyowa Hakko Kirin Co., Ltd., H1 2012
- Amgen Inc., H1 2012
- AstraZeneca PLC, H1 2012
- Eli Lilly and Company, H1 2012
- GlaxoSmithKline plc, H1 2012
- Seattle Genetics, Inc., H1 2012
- Genentech, Inc., H1 2012
- Merck & Co., Inc., H1 2012
- Emergent BioSolutions Inc., H1 2012
- Oxford BioMedica plc, H1 2012
- Light Sciences Oncology, Inc., H1 2012
- Novartis AG, H1 2012
- ImClone Systems Incorporated, H1 2012
- Astellas Pharma Inc., H1 2012
- Eisai Co., Ltd., H1 2012
- Ono Pharmaceutical Co., Ltd., H1 2012
- OSI Pharmaceuticals, Inc., H1 2012
- Pfizer Inc., H1 2012
- Taiho Pharmaceutical Co., Ltd., H1 2012
- Exelixis, Inc., H1 2012
- Alfacell Corporation, H1 2012
- Celgene Corporation, H1 2012
- Bayer AG, H1 2012
- MannKind Corporation, H1 2012
- 3SBio Inc., H1 2012
- EntreMed, Inc., H1 2012
- Celldex Therapeutics, Inc., H1 2012
- Active Biotech AB, H1 2012
- AEterna Zentaris Inc., H1 2012
- AIDA Pharmaceuticals, Inc., H1 2012
- Lorus Therapeutics Inc, H1 2012
- Bionomics Limited, H1 2012
- Northwest Biotherapeutics, Inc., H1 2012
- Cleveland BioLabs, Inc., H1 2012
- Patrys Limited, H1 2012
- Keryx Biopharmaceuticals, Inc., H1 2012
- ARQULE, INC, H1 2012
- Allos Therapeutics, Inc, H1 2012
- Flamel Technologies S.A., H1 2012
- Dendreon Corporation, H1 2012
- Green Cross Corporation, H1 2012
- MOLOGEN AG, H1 2012
- OncoTherapy Science, Inc., H1 2012
- Threshold Pharmaceuticals, Inc., H1 2012
- Innate Pharma SA, H1 2012
- Protox Therapeutics Inc., H1 2012
- Rexahn Pharmaceuticals, Inc., H1 2012
- Debiopharm Group, H1 2012
- Antisense Pharma GmbH, H1 2012
- Wilex AG, H1 2012
- Philogen S.p.A., H1 2012
- Cadila Pharmaceuticals Ltd., H1 2012
- ERYtech Pharma, H1 2012
- immatics biotechnologies GmbH, H1 2012
- Curacyte AG, H1 2012
- Argos Therapeutics, Inc., H1 2012
- Cytheris SA, H1 2012
- Altor BioScience Corporation, H1 2012
- AgrenVec, S.L., H1 2012
- Alethia Biotherapeutics Inc., H1 2012
- Gene Signal International SA., H1 2012
- MacroGenics, Inc., H1 2012
- Pivotal BioSciences, Inc., H1 2012
- Neotropix, Inc., H1 2012
- Jennerex Biotherapeutics, Inc., H1 2012
- Endocyte, Inc., H1 2012
- Advenchen Laboratories, LLC, H1 2012
- Immutep S.A., H1 2012
- Syndax Pharmaceuticals, Inc., H1 2012
- Esperance Pharmaceuticals, Inc., H1 2012
- Welichem Biotech Inc., H1 2012
- Tigris Pharmaceuticals, Inc., H1 2012
- AVEO Pharmaceuticals, Inc., H1 2012
- KAHR medical Ltd., H1 2012
- Advanced Cancer Therapeutics, H1 2012
- Medical Enzymes AG, H1 2012
- IkerChem S.L., H1 2012
- Immunovative Therapies, Ltd., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Kidney Cancer Therapeutics - Drug Profile Updates
- Kidney Cancer Therapeutics - Discontinued Products
- Kidney Cancer Therapeutics - Discontinued Products (Contd..1)
- Kidney Cancer Therapeutics - Discontinued Products (Contd..2)
- Kidney Cancer Therapeutics - Discontinued Products (Contd..3)
- Kidney Cancer Therapeutics - Dormant Products
- Kidney Cancer Therapeutics - Dormant Products (Contd..1)
- Kidney Cancer Therapeutics - Dormant Products (Contd..2)
- Kidney Cancer Therapeutics - Dormant Products (Contd..3)
- Kidney Cancer Therapeutics - Dormant Products (Contd..4)
- Kidney Cancer Therapeutics - Dormant Products (Contd..5)
- Kidney Cancer Therapeutics - Dormant Products (Contd..6)
- Kidney Cancer Therapeutics - Dormant Products (Contd..7)
- Kidney Cancer Therapeutics - Dormant Products (Contd..8)
- Kidney Cancer Therapeutics - Dormant Products (Contd..9)
- Kidney Cancer Therapeutics - Dormant Products (Contd..10)
- Kidney Cancer Therapeutics - Dormant Products (Contd..11)
- Kidney Cancer Therapeutics - Dormant Products (Contd..12)
- Kidney Cancer Therapeutics - Dormant Products (Contd..13)
- Kidney Cancer Therapeutics - Dormant Products (Contd..14)
- Kidney Cancer Therapeutics - Dormant Products (Contd..15)
- Kidney Cancer Therapeutics - Dormant Products (Contd..16)
- Kidney Cancer Therapeutics - Dormant Products (Contd..17)
- Kidney Cancer Therapeutics - Dormant Products (Contd..18)
- Kidney Cancer Therapeutics - Dormant Products (Contd..19)
- Kidney Cancer Therapeutics - Dormant Products (Contd..20)
- List of Figures
- Number of Products under Development for Kidney Cancer, H1 2012
- Products under Development for Kidney Cancer - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|